What evidence supports using empagliflozin (Jardiance) 25 mg daily as an adjunct antihypertensive in adults with type 2 diabetes and hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Empagliflozin 25 mg Daily as Antihypertensive Agent

Empagliflozin 25 mg daily provides modest but clinically meaningful blood pressure reduction (3-5 mmHg systolic) in adults with type 2 diabetes and hypertension, though it is not FDA-approved as a primary antihypertensive agent. The blood pressure-lowering effect is a beneficial secondary outcome that occurs alongside its primary glucose-lowering and cardiovascular protective effects 1.

Blood Pressure Reduction Evidence

The blood pressure-lowering effects of empagliflozin are well-documented across multiple studies:

  • Magnitude of effect: In the dedicated EMPA-REG BP trial, empagliflozin 25 mg reduced 24-hour ambulatory systolic blood pressure by -4.16 mmHg (95% CI: -5.50 to -2.83, P<0.001) and diastolic blood pressure by -1.72 mmHg (95% CI: -2.51 to -0.93, P<0.001) compared to placebo over 12 weeks 2. Office blood pressure reductions were consistent with ambulatory monitoring 1.

  • Monotherapy data: In the FDA label studies, empagliflozin 25 mg reduced systolic blood pressure by -3.4 mmHg (placebo-corrected, p=0.0028) at week 24 1.

  • Add-on to metformin: When combined with metformin, empagliflozin 25 mg reduced systolic blood pressure by -4.8 mmHg (placebo-corrected, p<0.0001) 1.

Mechanism of Blood Pressure Reduction

The antihypertensive effect occurs through multiple complementary mechanisms 3:

  • Natriuresis and osmotic diuresis from inhibiting renal tubular glucose reabsorption
  • Modest weight loss (approximately 2-3% body weight reduction)
  • Reduction in arterial stiffness and vascular resistance 4
  • Decreased cardiac workload through reduced pulse pressure and mean arterial pressure 4
  • No reflex tachycardia - heart rate remains stable or slightly decreases 5

Importantly, empagliflozin does not increase sympathetic nervous system activity despite lowering blood pressure, which distinguishes it from traditional diuretics 5.

Efficacy Across Hypertension Severity

The blood pressure-lowering effect is consistent regardless of baseline antihypertensive medication burden 6:

  • Patients on 0 antihypertensives: -3.77/-2.45 mmHg (25 mg dose)
  • Patients on 1 antihypertensive: -4.27/-1.81 mmHg (25 mg dose)
  • Patients on ≥2 antihypertensives: -4.17/-1.54 mmHg (25 mg dose)

In resistant hypertension (≥3 antihypertensive drugs including a diuretic with uncontrolled BP, or ≥4 drugs with controlled BP), empagliflozin reduced systolic blood pressure by -4.5 mmHg (95% CI: -5.9 to -3.1, P<0.001) at 12 weeks 7. This population comprised 22.5% of the EMPA-REG OUTCOME trial 7.

Recent meta-analyses confirm SGLT2 inhibitors provide modest incremental benefit in resistant/uncontrolled hypertension with acceptable safety 8.

Cardiovascular and Mortality Benefits

The primary rationale for using empagliflozin in patients with type 2 diabetes and cardiovascular disease is its proven reduction in cardiovascular death and heart failure hospitalization, not blood pressure control per se 3.

In EMPA-REG OUTCOME (7,020 patients with type 2 diabetes and established cardiovascular disease) 3:

  • Cardiovascular death or heart failure hospitalization: HR 0.83 (95% CI: 0.73-0.95, P=0.005)
  • Heart failure hospitalization alone: HR 0.73 (95% CI: 0.61-0.88)
  • Cardiovascular death: HR 0.62 (95% CI: 0.49-0.77, P<0.001)
  • All-cause mortality: HR 0.68 (95% CI: 0.57-0.82)

These benefits occurred independent of baseline blood pressure, A1c, or lipid levels 3.

Guideline Recommendations

Current guidelines recommend SGLT2 inhibitors primarily for cardiovascular and renal protection in type 2 diabetes, with blood pressure reduction as a favorable secondary effect 9, 10, 9, 11:

  • Strong recommendation for empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce heart failure hospitalization and death 11
  • Strong recommendation for SGLT2 inhibitors in heart failure with reduced ejection fraction (HFrEF), with or without diabetes 11
  • FDA indication for empagliflozin to reduce cardiovascular death in adults with type 2 diabetes and cardiovascular disease 9

The 2018 ACC Expert Consensus explicitly states empagliflozin should be considered in patients with type 2 diabetes and established cardiovascular disease, emphasizing cardiovascular outcomes over glycemic control 12.

Practical Implementation

If using empagliflozin 25 mg as adjunctive antihypertensive therapy:

  1. Primary indication: Patient must have type 2 diabetes with either:

    • Established cardiovascular disease, OR
    • Multiple cardiovascular risk factors, OR
    • Chronic kidney disease with albuminuria

  2. Renal function requirements 12, 1:

    • eGFR ≥45 mL/min/1.73 m²: No dose adjustment required
    • eGFR <45 mL/min/1.73 m²: Do not initiate; discontinue if eGFR persistently below 45
    • Note: Cardiovascular benefits appear present down to eGFR 30, but glucose-lowering efficacy diminishes 12

  3. Dosing: Start 10 mg daily, may increase to 25 mg daily. The 25 mg dose provides marginally greater blood pressure reduction than 10 mg 1, 2.

  4. Expected blood pressure effect: Anticipate 3-5 mmHg systolic reduction over 12-24 weeks. This is additive to existing antihypertensive medications 6.

  5. Monitoring:

    • Blood pressure at 4-12 weeks
    • Renal function and electrolytes at 2-4 weeks (watch for volume depletion in elderly or those on loop diuretics)
    • Genital mycotic infections (10-15% risk in women, higher in uncircumcised men) 11

Safety Considerations

Common adverse effects 11, 1:

  • Genital mycotic infections (most common, typically manageable with antifungals)
  • Volume depletion/hypotension (rare, <1% in trials, but monitor in elderly or those on loop diuretics)
  • Urinary tract infections (no significant increase vs placebo in meta-analyses 13, 8)
  • Diabetic ketoacidosis (rare, contraindicated in type 1 diabetes)

No increased risk of acute kidney injury, hypoglycemia (when not combined with insulin/sulfonylureas), or serious adverse events compared to placebo 13, 8.

Volume depletion risk is minimal - only 1 patient in the EMPA-REG BP trial reported volume depletion events 2. However, use caution in patients >75 years, those on loop diuretics, or with baseline eGFR 30-60 mL/min/1.73 m².

Clinical Context

Empagliflozin should not be prescribed solely for blood pressure control. Traditional antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics) provide greater blood pressure reduction and are first-line therapy 12.

However, in patients with type 2 diabetes and hypertension who also have cardiovascular disease or high cardiovascular risk, empagliflozin provides:

  • Modest blood pressure reduction (3-5 mmHg systolic)
  • Significant cardiovascular mortality reduction (38% in EMPA-REG OUTCOME)
  • Heart failure hospitalization reduction (27-35%)
  • Renal protection
  • Weight loss (2-3 kg)
  • Improved glycemic control (HbA1c reduction 0.6-0.8%)

The blood pressure-lowering effect is consistent across all baseline antihypertensive regimens, including resistant hypertension, making it a valuable adjunctive agent in this high-risk population 7, 6.

Dose-Response Relationship

Recent Bayesian meta-analyses found no clear dose-response pattern for blood pressure reduction across SGLT2 inhibitor doses 13. The difference between empagliflozin 10 mg and 25 mg is modest (approximately 0.5-1 mmHg additional reduction with 25 mg) 1, 2. Therefore, starting with 10 mg is reasonable, with uptitration to 25 mg based on glycemic control and cardiovascular risk rather than blood pressure alone.

Key Caveats

  • Not FDA-approved as an antihypertensive - blood pressure reduction is a secondary benefit 1
  • Requires type 2 diabetes diagnosis for appropriate use
  • Contraindicated in type 1 diabetes 11
  • Limited data in eGFR <30 mL/min/1.73 m² 11
  • Effects are modest compared to dedicated antihypertensive agents
  • Primary value is cardiovascular and renal protection, not blood pressure control per se

References

8
Research

Efficacy and Safety of SGLT-2 Inhibitors in Patients with Uncontrolled or Resistant Hypertension: A Pilot Meta-Analysis of Randomized Clinical Trials.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026

Related Questions

Is Jardiance (empagliflozin) appropriate for a 75‑year‑old man with hypertension who is already taking three antihypertensive medications?
Can Jardiance (empagliflozin) help manage pulmonary hypertension?
For a patient taking metformin, empagliflozin (Jardiance), hydrochlorothiazide, nebivolol, and hydralazine, can metformin be reduced to 850 mg twice daily, empagliflozin increased to 25 mg daily, hydrochlorothiazide reduced to 12.5 mg, nebivolol tapered off slowly, and hydralazine increased to three times daily?
Can an adult patient with stable blood pressure and eGFR ≥45 mL/min/1.73 m² start lisinopril and Jardiance (empagliflozin) on the same day?
In a 42-year-old male with newly diagnosed type 2 diabetes mellitus, hypertension, alcoholic liver disease, and coronary artery disease (with left ventricular hypertrophy, diastolic dysfunction, and preserved ejection fraction), who is currently taking metformin, empagliflozin, telmisartan, amlodipine, hydrochlorothiazide, aspirin, rosuvastatin, and uric‑acid‑lowering therapy, should any additional medication be added or should the current regimen be continued?
Is warfarin associated with heavy menstrual bleeding in women of reproductive age?
Can a microcatheter be used to measure intravascular pressure during interventional radiology procedures?
How do I calculate cardiac output using the Fick principle?
What does soft‑tissue swelling and edema of the left retro‑bulbar fat indicate in a 5‑year‑old who was struck in the face by a baseball one day ago?
What is the recommended treatment for suspected psittacosis acquired from inhalation of dried bird droppings?
Which vaccinations are recommended for patients undergoing splenectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.